Alife Health, a developer of AI tools to advance in-vitro fertilisation (IVF), has signed a marketing partnership with Hamilton Thorne to enhance clinical decision-making.
Hamilton Thorne manufactures and markets precision laser systems, imaging systems, consumables, and services. The offerings are intended for Assisted Reproductive Technologies (ART) and Developmental Biology Research markets.
Under the partnership, Alife Health’s artificial intelligence (AI)-based Embryo Assist software will be integrated with Hamilton Thorne’s laser systems.
This will help embryologists create digital records of every embryo and use Alife Health’s clinical decision support (CDS) algorithm to identify the best embryos for transfer.
All US-based Hamilton Thorne clients will receive a three-month trial of the Embryo Assist technology.
Hamilton Thorne Americas clinical sales and customer success vice president Catherine Welch said: “Hamilton Thorne is dedicated to leveraging cutting-edge industry expertise to continually enhance our comprehensive suite of products and services.
“We prioritise partnerships with forward-thinking companies and top industry experts to collaborate on ways to expand customer-centric solutions that bring innovations to life.”
Embryo Assist software is an integrated tool for microscopes, enabling embryologists to easily capture images and data, enhancing lab quality control.
The IVF-focused technology company collaborated with US-based Ovation Fertility in February to pilot the Embryo Assist software.
The software features a CDS-based AI embryo ranking system that uses machine learning to identify embryos with the highest survival chances.
According to Alife Health, its scientific abstract has shown the potential of its CDS model.
The results showed the models performed comparably to manual grading by experienced embryologists. It can also provide laboratories with a new standard for embryo selection.
Alife Health product head and chief operating officer Melissa Teran said: “At Alife, we value the opportunity to partner with industry leaders with a demonstrated history of excellence in reproductive medicine.
“We are thrilled to partner with Hamilton Thorne to advance our mutual goal of using technology to provide the most effective care for individuals seeking to grow their family.”
The IVF-focused firm aims to personalise and modernise the IVF process using advanced AI technology, improving outcomes and enhancing care for everyone.
Alife Health partnered with several clinics and physicians to drive clinical advancements for patients worldwide.
In March this year, the firm partnered with Boston IVF to pilot Stim Assist software for IVF medication optimisation.
